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The current excite-
ment is because of
the use of this tech-
nology to guide
interventions in
trials that measure
clinical outcomes.
I am sure that
regardless of the
accuracy of these
measures of ana-
tomy, functional
significance, and
plaque behavior,
the integration of
these features will
still require the
judgment of the
increasingly wellin-
formed cardiologist.EDITOR’S PAGE
Is it Form or Function?
We, interventionalists and angiographers, are visual people. We study the geography of the terrain.
Some of the most discriminating and, therefore, most successful questions on the interventional
cardiology boards are those that require integration of 2-dimensional images into 3-dimensional
concepts. Beauty to us is a perfectly curved and symmetrical coronary artery tree at the completion
of a percutaneous coronary intervention (PCI). But in addition to the form, we, as an architect,
must also appreciate function. Now in the case of the coronary circulation, we are asked to favor
function over form. It may not come naturally to the visually gifted, but it is necessary.
Hemodynamics used to be a much more prominent component of cardiology training. With
the ascent of coronary angiography, coronary anatomy took center stage in the catheterization
laboratory. However, we should remember that interventional cardiology was born with the
experiments that documented that a pressure drop across an artificially-created stenosis could
be eliminated by balloon expansion (Fig. 1). Now 35 years after the first angioplasty cases were
performed with balloons mounted on fluid-filled catheters attached to pressure manometers, we
have gone back to the future and pressure measurements or fractional flow reserve (FFR) is
reasserting the importance of function. This time it is not so much to document the result of
angioplasty (stenting), but to determine if the unattractive form (the stenosis), nonetheless, has
appealing function (adequate flow reserve).
In this issue of JACC: Cardiovascular Interventions, we once again present a mini-focus on
FFR with 4 original papers and 2 editorial comments. Truly we could fill the entire issue with
papers investigating or using this technology. The evaluation and application of FFR will
undoubtedly occupy significant space in issues to come. Despite the clear documentation that
visually identified stenoses may not reflect functional significance, the technology is
underutilized. Some laboratories still do not have FFR and some operators do not use it.
Guidelines have endorsed the use of FFR in stenoses of intermediate severity, especially when
noninvasive ischemia in that zone has not been documented. Correctly performed, FFR
measurements often surprise the angiographer, but provide clear documentation that an
interventional procedure on that lesion can or cannot improve the flow capability. Most lesions
do not require this measure as they are so severe as to almost always restrict flow, or so mild as
to seldom do so. Also, perfusion information may be clear from noninvasive testing.
Instrumenting such lesions would be inappropriate. The performance of FFR is critical in
obtaining accurate measures at the time of maximal hyperemia. Although central venous
administration is the gold standard for FFR, peripheral venous or intracoronary administration
are often practiced for convenience. A previous publication documented that increasing doses
of intracoronary adenosine from 60 to 720 g resulted in progressively decreasing FFR values
(1). Alternative agents have also been tested (2). Serial stenoses in arteries (3) and left main stenosis
(4) provide special challenges. However, the attention to FFR would not be so great if it only
mproved the assessment of the lesion significance. The current excitement is because of the use of
his technology to guide interventions in trials that measure clinical outcomes. The Deferral Versus
erformance of PTCA in Patients Without Documented Ischemia (DEFER) trial (5), that showed
atients with lesions having FFR 0.75 were not benefited by stenting, and the FAME trial (6)
hat showed that the use of FFR to guide intervention was associated with better outcomes and
ower costs than using angiography alone, are prime examples.
I was at the presentation of the Fractional Flow Reserve versus Angiography for Multivessel
valuation (FAME) II results during the European Society of Cardiology (ESC) meeting in
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1096Munich. Much of the drama of this trial and whether it
would be a counterweight to the Clinical Outcomes
Utilizing Revascularization and Aggressive Drug Evaluation
(COURAGE) trial was dampened by the earlier press
releases announcing its premature termination. As everyone
now knows, the trial, using FFR to confirm that the lesions
were truly capable of producing ischemia in a major territory,
was positive. The disappointment was that the early
termination based on urgent revascularization excess in the
medically treated group made this the component that drove
the decision for termination. It appeared from the Kaplan-
Meier curves of myocardial infarction that this more
universally accepted endpoint could have achieved a
difference if the trial continued. Nonetheless, stopping was
the call of the trialist and we should not second guess that
decision. This was not a trial of FFR, but used the
technology to establish a population who we would
expect to benefit from PCIs to a greater extent than
would have those in the COURAGE trial. Also at the
ESC meeting, papers were presented on computed
tomography angiography (CTA)-FFR and on CTA
combined with perfusion measures. It is unclear which of
these methods of noninvasively measuring form and
function of coronary stenoses will prevail, but it is clear
that the technology is progressing and some day there
may be integrated diagnostic tests that establish both
form and function to enable selection of appropriate
interventions for stable coronary disease patients. When
that day comes, will we be finished? Not by a long
shot. The next step will be to add to form and
function the capability to predict the future behavior of
Figure 1. Experimental PTCA From Andreas Gruentzig’s Presentation at Amthe lesions. Plaque composition and its predictive valuewill be the next frontier and may require invasive
investigation. We welcome with anticipation papers
reporting the results of studies using all of these
technologies to improve our clinical decision making.
I am sure that regardless of the accuracy of these
measures of anatomy, functional significance, and
plaque behavior, the integration of these features will
still require the judgment of the increasingly well-
informed cardiologist. And, that is a good thing!
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